British Columbia Cancer Agency

Public institution / office


Location: Vancouver, Canada (CA) CA

ISNI: 0000000107023000

ROR: https://ror.org/03sfybe47

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2023) Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, et al. Journal article Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer (2023) Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, et al. Journal article Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. (2022) Meagher NS, Gorringe KL, Wakefield MJ, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, et al. Journal article A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer (2021) Kaidar-Person O, Dahn HM, Nichol AM, Boersma LJ, de Ruysscher D, Meattini I, Pignol JP, et al. Journal article INTERNATIONAL EXPERT DELPHI CONSENSUS GUIDELINES FOR THE USE OF BOLUS IN POST MASTECTOMY RADIATION THERAPY (2021) Dahn H, Boersma L, De Ruysscher D, Meattini I, Offersen B, Pignol JP, Aristei C, et al. Conference contribution THE USE OF BOLUS IN POSTMASTECTOMY RADIATION THERAPY FOR BREAST CANCER: A SYSTEMATIC REVIEW (2021) Dahn H, Boersma L, De Ruysscher D, Meattini I, Offersen B, Pignol JP, Belkacemi Y, et al. Journal article Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article The use of bolus in postmastectomy radiation therapy for breast cancer: A systematic review (2021) Dahn HM, Boersma LJ, de Ruysscher D, Meattini I, Offersen BV, Pignol JP, Aristei C, et al. Journal article, Review article Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis (2021) Gelmon KA, Fasching P, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, et al. Journal article